Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease | Zendy

Ahai Luvai | Zendy; Wycliffe Mbagaya | Zendy; Alistair S. Hall | Zendy; Julian H. Barth | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rosuvastatin: A Review of the Pharmacology and Clinical Effectiveness in Cardiovascular Disease

Author(s) -

Ahai Luvai,

Wycliffe Mbagaya,

Alistair S. Hall,

Julian H. Barth

Publication year - 2012

Publication title -

clinical medicine insights cardiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.634

H-Index - 21

ISSN - 1179-5468

DOI - 10.4137/cmc.s4324

Subject(s) - rosuvastatin , medicine , clinical trial , pharmacology , hmg coa reductase , rosuvastatin calcium , statin , pharmacokinetics , clinical practice , medline , intensive care medicine , bioinformatics , reductase , physical therapy , chemistry , enzyme , biology , biochemistry

Rosuvastatin is a new generation HMG-CoA reductase inhibitor which exhibits some unique pharmacologic and pharmacokinetic properties. It has low extrahepatic tissue penetration, low potential for CYP3A4 interactions and substantial LDL-C lowering capacity and therefore has distinct advantages. We conducted a Medline literature search to identify rosuvastatin papers published in English. In this review, we outline the pharmacology of rosuvastatin, highlighting its efficacy and safety. We also review the major clinical trials with reference to primary and secondary prevention, familial hypercholesterolaemia and comparison with other statins. Finally we address its place in clinical practice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research